Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Depreciation & Amortization - Total (2024 - 2025)

Protalix BioTherapeutics has reported Depreciation & Amortization - Total over the past 2 years, most recently at $387000.0 for Q4 2025.

  • Quarterly results put Depreciation & Amortization - Total at $387000.0 for Q4 2025, up 15.87% from a year ago — trailing twelve months through Dec 2025 was $1.1 million (up 13.95% YoY), and the annual figure for FY2025 was $1.5 million, up 12.35%.
  • Depreciation & Amortization - Total for Q4 2025 was $387000.0 at Protalix BioTherapeutics, up from $372000.0 in the prior quarter.
  • Over the last five years, Depreciation & Amortization - Total for PLX hit a ceiling of $387000.0 in Q4 2025 and a floor of $319000.0 in Q2 2024.